Though we were supported by convincing data that sEH inhibitor TPPU ameliorates Alzheimer’s-like complications, TPPU should be further evaluated using Alzheimer’s disease-specific models. This evidence concerns the gene EPHX2 and early-onset autosomal dominant Alzheimer disease.